Psychedelic Drugs Market Surges as Therapeutic Potential Gains Recognition

Posted on 2023-06-12 by Fact.MR in Healthcare // 0 Comments

The psychedelic drugs market has witnessed significant growth and attention in recent years. Psychedelic substances, such as psilocybin (found in magic mushrooms) and MDMA (commonly known as ecstasy), have been studied for their potential therapeutic benefits in treating mental health disorders like depression, anxiety, and PTSD. The growing acceptance of psychedelic therapies and the relaxation of regulations surrounding these substances have fueled the market’s expansion.

Numerous clinical trials and research studies have demonstrated promising results in using psychedelics for therapeutic purposes. As a result, pharmaceutical companies, startups, and research institutions have shown increased interest in developing psychedelic-based medications. This has led to a surge in investment and collaborations within the psychedelic drugs market. Additionally, the growing public awareness and changing societal attitudes toward mental health have contributed to the market’s growth, as more individuals seek alternative treatment options beyond traditional pharmaceuticals. However, it is important to note that the psychedelic drugs market is still in its early stages, and there are regulatory challenges and potential risks associated with the use of these substances. As research progresses and more evidence is gathered, the market is expected to evolve and potentially disrupt the mental health treatment landscape

Download Free Sample Copy of this Report – https://www.factmr.com/connectus/sample?flag=S&rep_id=7028

Key Takeaways from Market Study

By source, synthetic production is expected to hold 75.6% market value share by the end of 2031, primarily due to the availability of active pharmaceutical products for formulations.
By therapeutic drug, psilocybin is expected to hold over 43% market share through its success in clinical trials for a varied range of mental health indications.
Based on indication, depressive disorders are leading factors for market growth and are subject to increase their impact to 22.3% share over the forecast period.
Medications with oral route of administration lead the psychedelic drugs market and are expected to progress at a CAGR of 6.6%, in the form of capsules, tablets, and liquids.
Hospital pharmacies dominated the market with a share of 56.1% in 2020.
By region, North America is set dominate the global market with a value share of around 60% by end of 2031. Europe is slated to be the second-largest leading market with a value share of 21.5%.

Country-wise Insights

The acceptance and regulations surrounding psychedelic drugs vary significantly from country to country. Here are some country-wise insights into the psychedelic drugs market:

United States: The United States has been at the forefront of the psychedelic renaissance. Several cities and states have decriminalized or reduced the enforcement of laws against psychedelic substances, allowing for research, therapeutic use, and even recreational use in some cases. The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for psilocybin and MDMA-assisted therapies, expediting their development and potential approval as prescription medications.
Canada: Canada has also been a leader in psychedelic drug research and regulations. Health Canada has granted exemptions for certain individuals to use psilocybin-assisted therapy for end-of-life distress and has approved several clinical trials exploring the therapeutic potential of psychedelics. In August 2020, the country granted its first-ever legal exemption for patients to use psilocybin to treat their mental health conditions.
Netherlands: The Netherlands has a unique approach to psychedelic substances. While the recreational use of psychedelics is not officially legal, the country has a longstanding policy of tolerance towards the sale and use of psilocybin-containing “magic truffles.” These truffles are available in smart shops and can be consumed for personal use.
Brazil: Brazil has a rich history of traditional psychedelic practices, particularly with ayahuasca, a brew containing the psychedelic compound DMT. Ayahuasca has been used ceremonially by indigenous communities for centuries. The Brazilian government recognizes the religious and cultural significance of ayahuasca and has allowed its use within specific religious contexts.
United Kingdom: In the United Kingdom, psychedelic research has gained traction in recent years. The regulatory environment has become more receptive to clinical trials and research on psychedelics. The Imperial College London, for example, has been conducting studies on psilocybin-assisted therapy for depression and has received approval for conducting larger trials.

Get Customization on this Report for Specific Research Solutions – https://www.factmr.com/connectus/sample?flag=RC&rep_id=7028

Competitive Landscape

Research and development activities, collaborations, sponsorships, and partnerships have emerged as key growth strategies being adopted by psychedelic drug manufacturing companies. By focusing on these strategies, key stakeholders are expanding their geographic footprints and strengthening their existing product portfolios.

Matched content

Editor’s pick